

3 September 2026

Notice given under section 708A(5)(e) of *Corporations Act 2001* (Cth)

This notice is given by **BluGlass Limited** (ACN 116 825 793) (**BluGlass** or the **Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**).

On 2 September 2026, BluGlass issued 1,530,217 new fully paid ordinary shares (**New Shares**) to employees of the Company, in lieu of cash, in satisfaction of their FY26 short-term incentive award entitlements and 212,875 New Shares to a third party adviser of the Company in consideration for services delivered. The issue of 1,743,092 New Shares was announced in an Appendix 2A lodged with ASX today.

BluGlass confirms that:

1. the New Shares were issued to investors without disclosure under Part 6D.2 of the Act;
2. this notice is being given under section 708A(5)(e) of the Act;
3. as at the date of this notice, BluGlass has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to BluGlass; and
 - (b) section 674 and 674A of the Act,
4. as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Act that is required to be set out in this notice under section 708A(6)(e) of the Act.

Andrew Palfreyman
Company Secretary

This announcement has been approved for release by the Board of BluGlass.

For more information, please contact:

James Lennon, Automic Markets | +61 2 8072 1400 | james.lennon@automicgroup.com.au
Samuel Samhan, BluGlass CFO | ssamhan@bluglass.com

About BluGlass

BluGlass Limited (ASX:BLG) is a leading supplier of GaN laser diode products to the global photonics industry, focused on the industrial, defence, bio-medical, and scientific markets.

Listed on the ASX, BluGlass is one of just a handful of end-to-end GaN laser manufacturers globally. Its operations in Australia and the USA offer cutting-edge, custom laser diode development and manufacturing, from small-batch custom lasers to medium and high-volume off-the-shelf products.

The Company combines its proprietary low temperature, low hydrogen, remote plasma chemical vapour deposition (RPCVD) manufacturing process with advanced device design and fabrication to deliver differentiated laser solutions. With end-to-end capabilities spanning epitaxy, device design, fabrication, and testing, BluGlass is well-positioned to support critical next-generation photonics applications and sovereign supply chains.